Michael Huang, M.D.
Dr. Huang joined Regulus in August 2015 as Vice President, Clinical Development. Prior to joining Regulus, Dr. Huang served as Vice President, Clinical Development of Auspex Pharmaceuticals, Inc. (acquired by Teva Pharmaceutical Industries Ltd. in May 2015) and was responsible for providing project and clinical leadership across multiple programs focused on the treatment of central nervous system disorders. Prior to Auspex, Dr. Huang served in medical leadership roles at Santarus, Inc., Spectrum Pharmaceuticals, Inc., Phenomix Corporation and Valeant Pharmaceuticals International. His clinical and medical expertise has resulted in regulatory approvals of Potiga®, Zevalin®, Uceris® and Ruconest®. Dr. Huang received his Bachelor of Arts degree in molecular and cell biology from the University of California, Berkeley and an M.D. from the Chicago Medical School at Rosalind Franklin University. He completed his residency training in family medicine at the University of California, Irvine and is Board Certified in primary care medicine. Dr. Huang is the author or co-author of numerous peer-reviewed journal articles, abstracts and scientific publications.